Markt geschlossen· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent
Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe Cytek Biosciences and Sysmex Europe Collaborate Cytek Biosciences and Sysmex Europe have signed an agreement establishing a strategic collaboration to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. By combining their complementary technologies, the collaboration will provide an integrated, end-to-end clinical flow cytometry
The Japanese medical robotics company, a joint venture between Kawasaki and Sysmex, is preparing for a European launch after expanding in the Asia-Pacific region.
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2025 and is expected to reach USD 3.72 Billion in 2026 and is expected to reach around USD 12.47 Billion by 2035, at a CAGR of 14.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laborato
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Fluorescent In Situ Hybridization Probe Market size & share revenue was valued at approximately USD 1.14 Billion in 2025 and is expected to reach USD 1.23 Billion in 2026 and is expected to reach around USD 2.27 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fis
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.
The Japan in vitro diagnostics market is ripe for growth due to the aging population's demand for chronic illness management, technological innovations like AI, point-of-care devices, and supportive government policies. Key opportunities exist in laboratory and point-of-care testing, with reagents dominating market share.Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Japan In Vitro Diagnostics Market: Distribution by Test Type, Type of Offering, Type of Technology, Therapeutic Area, End Users and
The Saudi Arabia in vitro diagnostics (IVD) market is set for steady growth, driven by the increasing prevalence of chronic and infectious diseases and enhanced healthcare spending. Estimated to rise from US$ 820.36 million in 2025 to US$ 1.17 billion by 2034, the market is supported by technological advancements, governmental investments under Vision 2030, and a strong focus on early disease detection. Adoption of molecular diagnostics and automated systems is anticipated to fuel market demand,
If you are wondering whether Sysmex is now priced attractively after a rough stretch, you are not alone. This article will focus on what the current share price might be implying about its value. Sysmex shares last closed at ¥1,420.5, with returns of 2.8% over the past week, a 3.0% decline over the past month, and year to date and 1 year returns of 7.4% and 46.6% declines respectively, with a 47.6% decline over 3 years and a 59.5% decline over 5 years. Recent coverage of Sysmex has focused...
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Malaria Diagnostics Market size & share revenue was valued at approximately USD 0.90 Billion in 2025 and is expected to reach USD 0.95 Billion in 2026 and is expected to reach around USD 1.45 Billion by 2035, at a CAGR of 5.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Access B
By 2033, the Point of Care (POC) Diagnostics market is projected to reach a valuation of approximately US$ 105.22 billion, driven by an 8.60% CAGR from 2025. This robust growth is fueled by high demand for rapid and accessible testing, escalating global prevalence of infectious diseases, and breakthroughs in technology. POC diagnostics facilitate immediate results at patient care sites, enhancing clinical decision-making and patient outcomes. Key players leading this market, including Sysmex, Ab
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.